Livsayis™ (cemdisiran) Approved by the FDA as First and Only siRNA Therapy in Generalized Myasthenia Gravis and Only Treatment with Four-Times-a-Year Subcutaneous Dosing

The FDA approved Regeneron's Livsayis (cemdisiran) for generalized myasthenia gravis, the first siRNA therapy for this condition. Phase 3 trial results showed significant improvements over placebo. The drug is administered subcutaneously four times a year, but carries a Boxed Warning for serious infections.

Original reporting
Published Nov 18, 2026, 11:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 19, 2026, 2:56 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefRegulation
Primary signal
$REGN
Bullish
high confidence
Mentioned
$REGN
Relevance
7/10
AlphAI data visualization · based on quantisnow.com
Decision brief

The 30-second read

$REGNBullishMed
01

Why it matters

Regulatory approval provides a new revenue stream and positions Regeneron in the growing RNA‑therapy space, likely supporting its stock price.

02

Market read

The approval is a material regulatory event for Regeneron, creating a fresh catalyst for the stock and potentially influencing the biotech sector.

03

What to watch

Potential competition from other gMG treatments and the need for extensive physician education on subcutaneous dosing.

Relevance 7/10Novelty 9/10Timing: pre‑market today

Background

Regeneron (NASDAQ:REGN) expands its portfolio with Livsayis, the first siRNA therapy approved for generalized myasthenia gravis, showing 2.3‑point MG‑ADL improvement over placebo.

Company-level read

Ticker impact

$REGNBullishHigh confidence
Context

FDA approved Livsayis (cemdisiran) for generalized myasthenia gravis, adding a first‑in‑class siRNA therapy to Regeneron's pipeline.

Expected impact

likely upward pressure as investors price in future sales potential

Evidence & confidence

First siRNA therapy for gMG, strong Phase 3 data, and limited launch guidance create a clear upside catalyst.

Market effects

May boost broader biotech/neurology sector as investors anticipate similar RNA‑based therapies.

U.S. biotech stocks could see modest gains; limited immediate effect on other regions.

Regeneron's approval highlights RNA therapeutics, potentially influencing global biotech funding trends.

Counterpoint

Boxed warning and REMS program could limit uptake; sales timeline and reimbursement uncertainty may temper upside.

Key entities

  • Regeneron Pharmaceuticals Inc.

    US‑listed biotech company receiving FDA approval for Livsayis.

  • Livsayis (cemdisiran)

    First siRNA therapy approved for generalized myasthenia gravis.

Related articles

$LLYMedAI 8/10

Rx Rundown: Ollin Biosciences, AstraZeneca, Isomorphic Labs and more

Eli Lilly, AbbVie, Johnson & Johnson, and others announced major deals and acquisitions in the biopharma sector, totaling billions. AstraZeneca, Roche, and Novo Nordisk received FDA approvals for new treatments. Isomorphic Labs raised $5 billion in private financing. AstraZeneca cut 600 jobs, while Cellectis plans to cut 70% of its workforce.

$REGNHigh

Argus raises Regeneron stock price target on Dupixent strength

Argus raised its price target for Regeneron (REGN) to $1,050, citing strong growth in Dupixent sales, which rose 35% to $6.54B in Q3 2026. REGN's revenue grew 19% YoY, with analysts revising earnings estimates upward. The company's partnership with Sanofi now generates more revenue than its Eylea franchise. Other drugs like Libtayo and Praluent also showed significant sales growth. REGN's pipeline includes cenvacibart, with estimated peak sales of $2B-$4B if approved.

$SNYMed

Sanofi and Regeneron’s rare disease wins; Lilly’s dealmaking dance

Sanofi received FDA approval for Infilbray, the first treatment for neurological symptoms of type 3 Gaucher disease. Regeneron's Livsayis, for generalized myasthenia gravis, also gained approval but faces competition. Eli Lilly announced two cancer-focused deals: a $5.9B research agreement with Stipple Bio and a $1.5B acquisition of Calytrix Bio. Lilly's weight loss drugs face new FDA safety warnings.

$REGNMed

EC Approves Extended Cemiplimab Dosing in Skin, Lung, and Cervical Cancers

The European Commission approved an extended dosing schedule for cemiplimab (Libtayo), a cancer drug by Regeneron Pharmaceuticals, across all approved indications in skin, lung, and cervical cancers. The new schedule allows 700 mg every 6 weeks after 12 weeks of 350 mg every 3 weeks, with shorter infusion times. The decision follows a positive opinion from the European Medicines Agency. According to Regeneron, this aims to reduce patient burden and increase healthcare flexibility.

$REGNMed

FDA Approves First siRNA Therapy for AChR-Positive Myasthenia Gravis

Regeneron's Cemdisiran (Livsayis) received FDA approval for treating AChR-positive generalized myasthenia gravis (gMG). The siRNA therapy, dosed quarterly, showed significant improvements in clinical trials. Regeneron estimates 85,000 US patients may benefit. The therapy carries a boxed warning for meningococcal infections. Regeneron did not disclose launch date or pricing.

$REGNMed

REGN Gets FDA Nod for Livsayis in Generalized Myasthenia Gravis

Regeneron Pharmaceuticals received FDA approval for Livsayis, a siRNA therapy for generalized myasthenia gravis (gMG). It is the first of its kind and is administered subcutaneously four times a year. The approval was based on positive phase III NIMBLE study results, showing significant symptom improvement. Livsayis carries a Boxed Warning for serious infections. Regeneron's stock has risen 22.9% year-to-date. The therapy is under review in the EU and planned for other regions.